Testing effectiveness (Phase 2)Looking for participantsNCT06534060What this trial is testingMB-105 in Patients With CD5 Positive T-cell LymphomaWho this might be right forLymphoma, T-Cell March Biosciences Inc 46
Early research (Phase 1)Active Not RecruitingNCT04072458What this trial is testingA Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesWho this might be right forMantle Cell LymphomaPeripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)+7 more Bio-Path Holdings, Inc. 30
Early research (Phase 1)Study completedNCT01902225What this trial is testingPhase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell LymphomaWho this might be right forLymphomaT-Cell LymphomaCutaneous Lymphoma Weiyun Ai 24
Testing effectiveness (Phase 2)UnknownNCT04626908What this trial is testingClinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin LymphomaWho this might be right forRelapsed and RefractoryLymphoid Hematological Malignancies He Huang 18
Not applicableLooking for participantsNCT02848274What this trial is testingID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeWho this might be right forMycosis FungoidesNon-Hodgkin's Lymphoma Stanford University 2,000
Testing effectiveness (Phase 2)Study completedNCT03128359What this trial is testingHigh Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantWho this might be right forAcute LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more City of Hope Medical Center 38
Early research (Phase 1)Active Not RecruitingNCT05665062What this trial is testingAutologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic MalignanciesWho this might be right forCLL/SLLNHLMantle Cell Lymphoma+4 more Synthekine 36
Large-scale testing (Phase 3)Looking for participantsNCT04365036What this trial is testingA Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)Who this might be right forNK/T Cell Lymphoma Nos Sun Yat-sen University 207
Testing effectiveness (Phase 2)Study completedNCT03373071What this trial is testingAnti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHLWho this might be right forCD19-ALLCD19-LNH Bambino Gesù Hospital and Research Institute 29
Early research (Phase 1)Study completedNCT00005634What this trial is testingSuberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT03103971What this trial is testingHuJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaWho this might be right forRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+14 more Fred Hutchinson Cancer Center 55
Early research (Phase 1)Ended earlyNCT01088763What this trial is testingGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaWho this might be right forChildhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germinoma+43 more National Cancer Institute (NCI) 129
Testing effectiveness (Phase 2)WithdrawnNCT05936229What this trial is testingInterferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyWho this might be right forRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRefractory B Acute Lymphoblastic Leukemia+3 more Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)UnknownNCT00669812What this trial is testingHigh-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell LymphomaWho this might be right forLymphomaSmall Intestine Cancer Cancer Research UK 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07493330What this trial is testingGenotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLWho this might be right forPTCLRefractory Ruijin Hospital 86
Not applicableNo Longer AvailableNCT00419367What this trial is testingCompassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)Who this might be right forLymphoma, T-Cell, Cutaneous Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)Study completedNCT03239392What this trial is testingA Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCLWho this might be right forLGL LeukemiaCTCL Bioniz Therapeutics 50
Testing effectiveness (Phase 2)Looking for participantsNCT06213636What this trial is testingFourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).Who this might be right forAcute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more Essen Biotech 75
Testing effectiveness (Phase 2)WithdrawnNCT01101412What this trial is testingAntimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWho this might be right forChronic Myeloproliferative DisordersInfectionLeukemia+6 more M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT01401530What this trial is testingE7777 for the Treatment of Patients With Peripheral T-Cell LymphomaWho this might be right forPeripheral T-Cell Lymphoma Eisai Co., Ltd. 13